NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors
Retrieved on:
Friday, May 12, 2023
Auxilium, Glucagon-like peptide-1 receptor, OXM, Union of Sales and Marketing Professionals, Medical device, Senior, International Management Institute, Bhubaneswar, NASH, Esperion Therapeutics, Marketing, Abbott Laboratories, State university system, Business, Head, Sale, Political science, Esperies, Business administration, Investigational New Drug, GCGR, New York University Stern School of Business, GPR119, GLP1R, Sales and operations planning, Fatty liver disease, Growth, Commercial, Therapy, IND, Oxyntomodulin, Student Senators Council of New York University, Endo International, Pharmaceutical industry, Management
"Mark is a highly accomplished pharmaceutical industry executive with more than 30 years of industry experience, including many senior leadership positions," said Andrew I. Koven, Chairman of NeuroBo's Board of Directors.
Key Points:
- "Mark is a highly accomplished pharmaceutical industry executive with more than 30 years of industry experience, including many senior leadership positions," said Andrew I. Koven, Chairman of NeuroBo's Board of Directors.
- "I am excited to join the NeuroBo Board of Directors at such an important stage for the Company, especially during the advancement of the Company's two promising cardiometabolic assets," said Mr. Glickman.
- "I look forward to working with my fellow Directors and the NeuroBo leadership team as we position the Company for long-term growth and value creation."
- Prior to this role, he served as Chief Business Officer, Commercial of TherapeuticsMD, Inc. since June 2021.